A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in children, and currently, there are no FDA-approved therapies. Plasminogen activator inhibitor-1 (PAI-1) is elevated in children with NAFLD and associated with increased disease severity. Losartan potassium (losa...

Descripción completa

Detalles Bibliográficos
Autores principales: Vos, Miriam B., Jin, Ran, Konomi, Juna V., Cleeton, Rebecca, Cruz, Jessica, Karpen, Saul, Rodriguez, Dellys Soler, Frediani, Jennifer K., McCracken, Courtney, Welsh, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987658/
https://www.ncbi.nlm.nih.gov/pubmed/29992039
http://dx.doi.org/10.1186/s40814-018-0306-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987658/
https://www.ncbi.nlm.nih.gov/pubmed/29992039
http://dx.doi.org/10.1186/s40814-018-0306-4

Ejemplares similares